Our Clients

OHE Consulting's diverse clientele includes government agencies, international organisations and foundations, national foundations and think tanks, health charities and non-profit groups, the life sciences industries, trade associations and academia.

Selected Clients

  • ABPI
  • Alzheimer's Research UK
  • Amgen Inc.
  • Astellas
  • Association of British Healthcare Industries
  • AstraZeneca
  • Bill & Melinda Gates Foundation
  • British Lung Foundation
  • Cancer Research UK
  • Celgene
  • The Cord Blood Charity
  • Department of Health (England)
  • Eisai Ltd
  • Eli Lilly and Company
  • European Commission
  • German Federal Ministry of Health
  • GlaxoSmithKline
  • International AIDS Vaccine Initiative
  • International Public Private Partnership for Health
  • Janssen-Cilag Ltd.
  • Merck Sharp & Dohme
  • Medical Research Council
  • Novartis
  • NovoNordisk
  • OECD
  • Pfizer
  • Roche
  • Rockefeller Foundation
  • Sanofi-Synthelabo
  • VFA (Germany)
  • Wellcome Trust
  • World Bank
  • World Health Organisation

What They Say

“OHE's counsel was extremely beneficial on how to participate in the European policy debate and help create a better environment for the development, licensing and market access of our product line. Our company is using this advice to become more actively involved in European discussions.”
Vice President, Government Affairs

"The PRO analyses you have performed for us have been extremely useful -- the adjusted utilities, analysis of EQ-5D profiles, and mapping work have all helped with the health economics modelling we are doing to support reimbursement and HTA, and are also adding to the body of evidence to help us differentiate our products."
Director, Health Economics and Outcomes Research, Astellas Pharma Europe Ltd

“The workshop [on value-based pricing] was expertly delivered by the OHE, which brought a wealth of experience on the various methodologies being considered.”
Health Economics Manager at a top-20 global pharmaceutical company

"Drawing on her expertise on the measurement of patient reported outcomes, Professor Devlin armed us with valuable insights into the changing environment and the implications for the pharmaceutical industry."
Senior Manager, Janssen